Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Change in Account Payables: 2019-2025

Historic Change in Account Payables for IDEAYA Biosciences (IDYA) over the last 7 years, with Sep 2025 value amounting to $1.2 million.

  • IDEAYA Biosciences' Change in Account Payables rose 130.24% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year decrease of 7.35%. This contributed to the annual value of $8.3 million for FY2024, which is 214.23% up from last year.
  • As of Q3 2025, IDEAYA Biosciences' Change in Account Payables stood at $1.2 million, which was up 427.20% from -$364,000 recorded in Q2 2025.
  • Over the past 5 years, IDEAYA Biosciences' Change in Account Payables peaked at $9.7 million during Q2 2024, and registered a low of -$3.9 million during Q3 2024.
  • For the 3-year period, IDEAYA Biosciences' Change in Account Payables averaged around $1.3 million, with its median value being $1.2 million (2025).
  • Its Change in Account Payables has fluctuated over the past 5 years, first surged by 5,771.43% in 2022, then crashed by 3,675.00% in 2024.
  • Over the past 5 years, IDEAYA Biosciences' Change in Account Payables (Quarterly) stood at -$7,000 in 2021, then spiked by 5,771.43% to $397,000 in 2022, then spiked by 339.55% to $1.7 million in 2023, then spiked by 70.54% to $3.0 million in 2024, then soared by 130.24% to $1.2 million in 2025.
  • Its Change in Account Payables was $1.2 million in Q3 2025, compared to -$364,000 in Q2 2025 and $2.7 million in Q1 2025.